Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer’s Dacomitinib And More Biosimilar Hopefuls Among New EMA Filings

Executive Summary

There are eight new entries to the list of marketing applications filed with the European Medicines Agency, including submissions for more versions of Amgen’s Neulasta (pegfilgrastim), and a second biosimilar of Roche’s Avastin (bevacizumab).

You may also be interested in...



EU Safety Updates For Lenalidomide, Pegfilgrastim & Pembrolizumab

The labeling of several major medicines marketed in the EU is to be updated to reflect cases of serious adverse events. The European Medicines Agency’s pharmacovigilance committee has also recommended a new warning on drug-drug interactions, and asked for additional information on several other products.

ATMP For Metastatic Cervical Cancer Among Nine New Products Under EMA Review

Nine new products have been added to the list of products that the European Medicines Agency is reviewing for marketing authorization.

Two Hopefuls And A ‘No’: EMA Decisions On Accelerated Access

Regeneron and Shire should find out this week whether the European Medicines Agency will agree to fast-track its review of their products.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS122693

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel